Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FX8N
|
|||
| Drug Name |
CT1812
|
|||
| Synonyms |
Elayta
Click to Show/Hide
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
Cognition Therapeutics Pittsburgh, PA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H33NO4S
|
|||
| Canonical SMILES |
CC(C)(C)OC1=C(C=CC(=C1)CCC(C)(C)N2CC3=C(C2)C=C(C=C3)S(=O)(=O)C)O
|
|||
| InChI |
1S/C24H33NO4S/c1-23(2,3)29-22-13-17(7-10-21(22)26)11-12-24(4,5)25-15-18-8-9-20(30(6,27)28)14-19(18)16-25/h7-10,13-14,26H,11-12,15-16H2,1-6H3
|
|||
| InChIKey |
ISQAPFMBJFZOLG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1802632-22-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sigma intracellular receptor 2 (TMEM97) | Target Info | Antagonist | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04735536) Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.